{'fraction_non_alphanumeric': 0.02635431918008785, 'fraction_numerical': 0.0, 'mean_word_length': 4.846153846153846, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Gray‐bluish cutaneous pigmentation and ice‐pick scars induced by vandetanib therapy

infection. Although the serum level of G-CSF is an effective biomarker in G-CSF-producing tumors, its measurement is not widely available. In addition, the acquired resistance of dabrafenib and trametinib was detected by the WBC count earlier than by the serum level of LDH. In this context, it may be possible to regard the WBC count as a surrogate marker in the treatment of G-CSF-producing melanoma. In conclusion, considering the aggressive nature of this melanoma, timely monitoring of the treatment response and resistance is important. The WBC count may be a good marker for such monitoring.